Insights & news

Dutch Competition Authority Presents Findings of Sector Inquiry of TNF-Inhibitors

  • 25/09/2019
  • Articles

The Dutch Competition Authority “Autoriteit Consument & Markt” (“ACM”) published yesterday the findings that result from its sector inquiry of TNF-inhibitors on the hospital market (see attached press release and findings). ACM had started its sector inquiry in June 2018 over concerns that the significant costs of TNF-inhibitors may be caused in part by insufficient competition among suppliers (see, Van Bael & Bellis Life Sciences Newsflash of 28 June 2018). 
 
TNF-inhibitors are biological medicines used to treat autoimmune and immune-mediated disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and hidradenitis suppurativa. They attach to a substance in the body called tumour necrosis factor (“TNF”) which causes inflammation and is found at high levels in patients afflicted by these conditions. In blocking the activity of TNF, the TNF-inhibitors reduce inflammation and other symptoms of the diseases.
 
The inquiry of ACM focused on the five TNF-inhibitors on the Dutch market (namely infliximab; etanercept; adalimumab; certoluzimab pegol; and golimumab) but also considered possible therapeutic alternatives that present a different mechanism of action. At the same time, ACM expressly refrained from taking positions on issues such as relevant market or dominant position.
 
ACM observed a substantial decrease in prices following the expiry of the patents in three active substances (infliximab; etanercept; and adalimumab). According to ACM, the advent of biosimilars was an important factor, but the price reduction was facilitated by scientific studies showing no major obstacles to switching existing patients from one TNF-inhibitor to another.
 
Despite the inroads of biosimilars on the market, two originating active substances have succeeded in maintaining their leadership position in their category. ACM attributes the staying power of these medicines to a variety of organisational and educational factors but also cites the possible effects of what it refers to as “conditional discounts” which cause a hospital to lose the benefit of the price reduction if a group of patients are unwilling or unable to make a product switch.
 
ACM makes a number of policy recommendations for hospitals, insurers and the government and adds that it will not hesitate to enforce the competition rules if specific discounts used by suppliers have a foreclosure effect on the market.

 

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 12/02/2020
    • Articles

    UK Competition and Markets Authority Consolidates Hydrocortisone Probe On Account of Excessive Pricing and Other Competition Violations

    The UK Competition and Markets Authority announced this morning that it has issued a supplementary statement of objections (“SSO”) in its inquiry into alleged excessive and unfair pricing, anti-competitive agreements and abusive conduct in relation to the supply of hydrocortisone tablets in the UK (see, attachment). The CMA has been conducting three separate investigations in this matter and has issued previous statements of objections on four occasions between December 2016 and February 2019 (see, Van Bael & Bellis Life Sciences Newsflash of 6 March 2017). The new SSO has brought all these cases together and has allowed the CMA to reconsider specific aspects of its provisional findings in the previous statements of objections. The CMA accuses a range of companies, including Auden Mckenzie and its successor Accord-UK (previously: Actavis UK), Waymade and Advanz Pharma (previously: Concordia and AMCo), of having charged excessive and unfair prices for hydrocortisone tablets and having entered into agreements that cemented a prevailing dominant position on the market. The CMA also seeks to attribute liability to other parties which at various points in time had ownership of some of the accused firms. Hydrocortisone tablets are the primary treatment for people suffering from the life-threatening Addison's disease which causes adrenal glands to produce insufficient amounts of natural steroid hormones. According to the CMA, there are limited alternative treatments for hydrocortisone tablets.

    Read more
    • 07/02/2020
    • Articles

    Belgian Council of State Clarifies Role of Concerned Member States in Decentralised Marketing Authorisation Procedure

    On 16 January 2020 the Belgian Council of State reaffirmed the limited discretionary powers of a concerned Member State to call into question the assessments carried out by the Reference Member State in a decentralised procedure. It relied heavily on the case law of the Court of Justice of the European Union in the field. Please find attached a note on the judgment as well as its text.

    Read more
    • 03/02/2020
    • Articles

    Belgium - Medicine Shortages

    The Belgian Official Journal publishes today a Law of 20 December 2019 modifying various laws to tackle medicine shortages (Wet van 20 december 2019 tot wijziging van diverse wetgevingen wat de tekorten aan geneesmiddelen betreft/Loi du 20 décembre 2020 modifiant diverses législations, en ce qui concerne les pénuries de medicaments – the Law). For a summary of the Law’s key features, we refer to the Van Bael & Bellis Life Sciences Newsflash of 20 December 2019. The Royal Decrees that will complement the Law have not yet been published. We understand this still may take some time. The Law will enter into force on 13 February 2020 (i.e., 10 days following its publication in the Belgian Official Journal), with the exception of Articles 2 and 4 that started to apply on 31 January 2020.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *